Executive Summary
Asset / Ticker: BioElectronics Corp (OTC: BIEL) & Electrome Corp (Private)
Event: Strategic Joint Venture & Commercial Platform Launch (Q1/Q2 2026) - Austin Startups, May 2026
A high-margin "Intel Inside" play for digital health. The deal marries an undervalued, OTC-traded hardware manufacturer possessing extensive FDA clearances with an agile, venture-backed AI therapeutics startup. This creates an immediate, scalable infrastructure to capture market share in the non-pharmacologic pain management sector (targeting the VA and CMS "No Pain" opioid-reduction programs).
Strategic Value Exchange
What Electrome Brings to the Table
The AI Care Layer: Provides the proprietary programmable software architecture (PAINKILLER™) that transitions static hardware into an integrated digital health ecosystem.
Commercial Acceleration: Spearheads institutional distribution workflows, deploying the platform directly into high-margin networks like the Veterans Health Administration (VA).
Modernized Monetization: Packages hardware into an AI-guided remote patient monitoring and evidence-generation ecosystem.
What BIEL Brings to the Table
Instant Regulatory Runway: Grants Electrome immediate access to established FDA 510(k) clearances for ActiPatch® (musculoskeletal pain) and RecoveryRx® (postoperative care).
Historical Safety Infrastructure: Supplies nearly three decades of clinical trial datasets and post-market safety data, eliminating years of R&D and clinical overhead.
Scalable Manufacturing: Delivers a fully mature supply chain capable of continuous production of Pulsed Shortwave Therapy (PSWT) devices at an estimated ~87% gross margin.
Austin Startups (austinstartups.com), a prominent regional startup ecosystem directory and venture tracker powered by Capital Factory (Texas's premier startup accelerator and venture fund). According to their investment profile, Electrome Corp is a member of the Capital Factory All Access Fund portfolio. The source details Electrome's operational blueprint, confirming that while the company has a multi-city footprint (SF, Boston, LA), its core early venture-backing and fundraising pipeline run directly through the Austin, Texas tech infrastructure.
Asset / Ticker: BioElectronics Corp (OTC: BIEL) & Electrome Corp (Private)
Event: Strategic Joint Venture & Commercial Platform Launch (Q1/Q2 2026) - Austin Startups, May 2026
A high-margin "Intel Inside" play for digital health. The deal marries an undervalued, OTC-traded hardware manufacturer possessing extensive FDA clearances with an agile, venture-backed AI therapeutics startup. This creates an immediate, scalable infrastructure to capture market share in the non-pharmacologic pain management sector (targeting the VA and CMS "No Pain" opioid-reduction programs).
Strategic Value Exchange
What Electrome Brings to the Table
The AI Care Layer: Provides the proprietary programmable software architecture (PAINKILLER™) that transitions static hardware into an integrated digital health ecosystem.
Commercial Acceleration: Spearheads institutional distribution workflows, deploying the platform directly into high-margin networks like the Veterans Health Administration (VA).
Modernized Monetization: Packages hardware into an AI-guided remote patient monitoring and evidence-generation ecosystem.
What BIEL Brings to the Table
Instant Regulatory Runway: Grants Electrome immediate access to established FDA 510(k) clearances for ActiPatch® (musculoskeletal pain) and RecoveryRx® (postoperative care).
Historical Safety Infrastructure: Supplies nearly three decades of clinical trial datasets and post-market safety data, eliminating years of R&D and clinical overhead.
Scalable Manufacturing: Delivers a fully mature supply chain capable of continuous production of Pulsed Shortwave Therapy (PSWT) devices at an estimated ~87% gross margin.
Austin Startups (austinstartups.com), a prominent regional startup ecosystem directory and venture tracker powered by Capital Factory (Texas's premier startup accelerator and venture fund). According to their investment profile, Electrome Corp is a member of the Capital Factory All Access Fund portfolio. The source details Electrome's operational blueprint, confirming that while the company has a multi-city footprint (SF, Boston, LA), its core early venture-backing and fundraising pipeline run directly through the Austin, Texas tech infrastructure.
2
